Cr Bard Inc: (NYSE: BCR)

$105.15

-0.13 (-0.12%)

Volume 678,946

May 23 04:02 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		104.22 - 105.28
	
		52wk Low - High
		93.69 - 108.31
	
		Previous Close
		105.28
	
		Avg. Volume
		638,546
	
		Industry
		MED/DENTAL-SUPP
	
		Market Cap
		8.66 B
	
		Div - Yield
		0.80 - 0.76
	
		Beta
		0.39
	
		PE (Forward)
		16.83
	
		Current Year Est.
		6.25
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		121 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 04/25/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            16.83
                        
                            PEG Ratio
                            1.77
                        
                            Current Year Est.
                            6.25
                        
                            Current Quarter Estimate
                            1.38
                        
                            Most Accurate Estimate
                            1.38
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            07-24-2013
                        
                            EPS Last Year
                            6.40
                        
                            Expected Earnings Growth
                            9.54%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
C.R. Bard, Inc. is one of the worldwide leaders in developing, manufacturing, and supplying healthcare products that focus on Vascular, Urology, and Oncology Disease States. In addition, Bard offers a complete line of advanced Surgical Specialty products and services that address needs in hernia repair, performance irrigation, hemostasis, and other areas.   
Full BCR Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
BCR Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	1.38	1.67	6.25	7.67
Number of Estimates	12	11	14	12
Low Estimate	1.37	1.55	6.00	7.47
High Estimate	1.40	1.75	6.30	NA
Year Ago EPS	1.62	1.64	6.57	6.25
EPS Growth	-14.66%	1.55%	-4.82%	22.66%

More BCR Estimates

Average Earnings Estimates for BCR

EPS Growth for BCR

Industry Analysis

Name	Symbol	Previous Close
BARD C R INC	BCR	105.28
LUXOTTICA ADR	LUX	54.12
ALPHATEC HLDGS	ATEC	1.91
CONMED CORP	CNMD	33.28
COOPER COS	COO	107.22
MWI VET SUPPLY	MWIV	120.00
STERIS CORP	STE	45.03
WEST PHARM SVC	WST	67.34
ALIGN TECH INC	ALGN	37.30
BECTON DICKINSO	BDX	100.02

Sector:Medical>> Industry:MED/DENTAL-SUPP

COMPARE TICKER vs. Its Peers

Zacks Commentary

Bard Beats on 1Q Earnings, Profit Slumps

Apr 24, 2013

Will CR Bard Miss Earnings this Quarter?

Apr 22, 2013

CR Bard Reiterated at Neutral

Mar 14, 2013

CR Bard Squarely Beats Estimates

Feb 01, 2013

Earnings Preview: CR Bard Inc.

Jan 30, 2013

Teleflex Wins GPO Agreement

Jan 22, 2013

Covidien Wins FDA Approval

Jan 22, 2013

Covidien Begins SWIFT PRIME Study

Jan 15, 2013

More BCR Zacks Commentary

Financials

EPS TTM	6.40
Sales	2,958
Net Income	482
Price/Earnings	16.45
Price/Book	4.56
Price/Cash Flow	12.35
Price/Sales	2.92

More BCR Financials

News

CR Bard Bullish Moving Average Crossover Alert (BCR) - Financial News Network Online - Moving Average Crossovers

May 22, 2013

Short-term Underperformance Detected in Shares of ABIOMED in the Health Care Equipment Industry (ABMD, EW, DXCM, WMGI, BCR) - Financial News Network Online - News Corner

May 22, 2013

CR Bard (BCR) Showing Bullish Technicals With Resistance At $107.45 - Freshbrewedmedia

May 16, 2013

Medical company agrees to pay $48.2 million in federal whistle-blower lawsuit filed by Macon woman - Mcclatchy-Tribune Information Services -- Unrestricted

May 15, 2013

C.R. Bard Inc. to Pay U.S. $48.26 Million to Resolve False Claims Act Claims - M2

May 14, 2013

Medical company agrees to pay $48.2 million in federal whistleblower lawsuit filed by Macon woman - Mcclatchy-Tribune Information Services -- Unrestricted

May 14, 2013

C.R. Bard Inc. to Pay U.S. $48.26 Million to Resolve False Claims Act Claims - Find Government Press Releases

May 13, 2013

C.R. Bard Inc. to Pay U.S. $48.26 Million to Resolve False Claims Act Claims - Find Government Press Releases

May 13, 2013

See All News Stories on BCR

Broker Recommendations

Current ABR	2.64
ABR (Last Week)	2.64
# of recs in ABR	16
Average Target Price	106.25
Industry Rank by ABR	121 out of 265
Rank in Industry	8 out of 29

More BCR Broker Recommendations

Day Low - High	104.22 - 105.28
52wk Low - High	93.69 - 108.31
Previous Close	105.28
Avg. Volume	638,546
Industry	MED/DENTAL-SUPP
Market Cap	8.66 B
Div - Yield	0.80 - 0.76
Beta	0.39
PE (Forward)	16.83
Current Year Est.	6.25
Quarterly Earnings ESP	0.00%

PE (Forward)	16.83
PEG Ratio	1.77
Current Year Est.	6.25
Current Quarter Estimate	1.38
Most Accurate Estimate	1.38
Earnings ESP	0.00%
Next Earnings Report Date	07-24-2013
EPS Last Year	6.40
Expected Earnings Growth	9.54%

Username: Password:

Remember me [?]

Cr Bard Inc: (NYSE: BCR)

$105.15

-0.13 (-0.12%)

Volume 678,946

May 23 04:02 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description